Immunoglobulin E–Fc-epsilon receptor I complex (IgE–FcεRI complex)

The Immunoglobulin E–Fc-epsilon receptor I complex is a high-affinity cell surface receptor-ligand system that is central to the effector phase of allergic responses. Fc-epsilon receptor I (FcεRI) is a multi-subunit receptor expressed primarily on mast cells and basophils, consisting of one alpha subunit (FcεRIα) that binds the Fc region of IgE, one beta subunit (FcεRIβ) that amplifies downstream signals, and a dimer of gamma subunits (FcεRIγ) responsible for initiatiating the intracellular signaling cascade[1][3][6][9]. When IgE bound to FcεRI is crosslinked by antigen (allergen), the complex triggers rapid cell activation, leading to degranulation and release of histamine and other pro-inflammatory mediators, which underlie the immediate symptoms of allergic reactions[2][4][6][7][9]. FcεRI is also found on other cell types, such as dendritic cells and eosinophils, but may lack the beta subunit in those contexts[6][7][9]. Drugs targeting this complex—particularly antibodies that block IgE from binding FcεRI (e.g., omalizumab)—are clinically validated therapies for allergic asthma and other IgE-mediated conditions. The complex plays a well-defined role in allergic diseases, and is a primary therapeutic target in allergy and asthma[2][7][9][10].

Other names

IgE–FcεRI complexImmunoglobulin E–Fc epsilon receptor I complexIgE high-affinity receptor complexFc epsilon RI–IgE complex

Blockade of IgE binding to FcεRI; Downregulation of FcεRI expression; Inhibition of IgE-mediated mast cell and basophil activation; Prevention of allergen-induced cross-linking.